Evidence map›Paper›PMID 33161491›Full record

ArticleThe AAPS journal2020

Monoclonal Antibody Reagent Stability and Expiry Recommendation Combining Experimental Data with Mathematical Modeling.

Malorie Fink, Erin Marie Cannon, Carl Hofmann, Nisarg Patel, Cindy Pauley, Matthew Troutman, Richard R Rustandi, Mary Shank-Retzlaff, John Loughney, Thorsten Verch

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Malorie FinkAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Erin Marie CannonAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Carl HofmannAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Nisarg PatelAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Cindy PauleyAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Matthew TroutmanAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Richard R RustandiAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Mary Shank-RetzlaffAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
John LoughneyAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Thorsten VerchAnalytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA. thorsten_verch@merck.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are widely used as critical reagents in analytical assays. While regulatory guidelines exist for stability monitoring of biopharmaceutical antibodies, they do not apply directly to the stability of mAbs used as assay reagent. We investigated alternative approaches to real-time stability monitoring of assay reagents. We compared functional (ELISA and cell-based) and biochemical (aggregation, deamidation) assay results using temperature-stressed mAb reagents. Data from both assay groups were compared for indications of antibody degradation. Arrhenius model kinetics was used to further extrapolate stability trends. Changes detected by traditionally monitored biochemical changes were not directly predictive of assay function. Instead, monitoring of reportable results was a closer indication of changes in assay performance related to mAb degradation. Using Arrhenius kinetic modeling, we combined forced degradation of individual reagents with reportable assay results to classify reagents into risk groups with associated re-evaluation and monitoring plans. This combined approach mitigates risk by monitoring each mAb reagent individually under stressed conditions while streamlining expiry assignment through simplified Arrhenius kinetics with only limited real-time stability data.

Indexed as

Protein DenaturationProteolysisAntibodies, MonoclonalArabidopsis ProteinsBiological AssayGuidelines as TopicIndicators and ReagentsLaboratoriesModels, BiologicalNuclear ProteinsQuality ControlAntibodies, MonoclonalArabidopsis ProteinsIndicators and ReagentsNuclear ProteinsTIC protein, ArabidopsisArrhenius kineticsexpirymonoclonal antibodyQ10 rulereagent stability

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.